Navigation Links
West Announces Third Quarter 2009 Results
Date:11/3/2009

ORMATION (UNAUDITED) (in millions) Three Months Ended Nine Months Ended September 30, September 30, ------------- ------------- Net Sales: 2009 2008 2009 2008 ---- ---- ---- ---- Pharmaceutical Systems $198.1 $190.5 $579.2 $610.6 Tech Group 62.9 68.3 192.0 204.3 Eliminations (2.1) (2.6) (8.9) (8.6) ---- ---- ---- ---- Consolidated Total $258.9 $256.2 $762.3 $806.3 ====== ====== ====== ====== Operating Profit (Loss): Pharmaceutical Systems $29.9 $23.1 $91.5 $107.0 Tech Group 2.6 5.1 13.4 13.5 General corporate costs (3.7) (3.9) (13.1) (14.0) Stock-based compensation expense (2.5) (3.1) (6.3) (7.1) U.S. pension expense (4.3) (1.5) (12.5) (4.5) Restructuring and other items 3.9 (1.8) 2.8 3.6 --- ---- --- --- Consolidated Total $25.9 $17.9 $75.8 $98.5 ===== ===== ===== ===== WEST PHARMACEUTICAL SERVICES NON-GAAP MEASURES (UNAUDITED) THREE MONTHS ENDED SEPTEMBER 30, 2009 (in millions, except per share data)
'/>"/>
SOURCE West Pharmaceutical Services, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6American Red Cross Wins Court Injunction Against Striking Teamsters 62584 1American Red Cross Wins Court Injunction Against Striking Teamsters 62584 2Senate Approval of Mikulski Amendment Further Opens Health Care Bill to Massive Federal Funding of Abortion 62581 1Senate Approval of Mikulski Amendment Further Opens Health Care Bill to Massive Federal Funding of Abortion 62581 2Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 1Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 2